CA-VERACODE
1.5.2024 14:51:32 CEST | Business Wire | Press release
Veracode, a global leader in application risk management, today announced platform innovations that set a new standard for developer-powered application security. New repo risk visibility and analysis from Longbow Security, powered by Veracode, speeds up remediation of application risk from code repositories to runtime images. The solution launches alongside Veracode Fix in the Integrated Development Environment (IDE) and Batch Fix to bridge the gap between development and security teams. These latest innovations help developers focus on the most critical tasks that drive value and differentiation.
“Developers today face significant competing pressures to innovate faster and perform more security checks on their code than ever before,” said Tim Jarrett, Group Head of Product Management at Veracode. “We are committed to a frictionless experience for developers and security operators and our latest product enhancements make the job of securing code simple and seamless.”
Bringing Developer & Security Teams Together: Repo Risk Visibility & Analysis
In April, Veracode acquired Longbow Security to help organizations effectively manage and reduce application risk across the growing attack surface. The integration of Longbow’s newest capability, repo risk visibility and analysis, bridges the gap between development and security teams with enhanced visibility from code repositories to cloud assets and runtime images. It also illuminates infrastructure-as-code and misconfiguration risk for cloud assets originating from repositories.
“Customers challenged us to apply our unique cloud risk and prioritization expertise from Longbow to problems they face managing upstream risk in their code repositories,” said Derek Maki, Vice President of Product Management at Veracode. “We responded with a solution that gives visibility into the relationship between source code weaknesses and runtime security posture. Simultaneously, development teams get a consolidated view of risk and huge time savings when it comes to prioritizing remediation, reducing code changes, and fixing issues fast.”
This new feature complements Veracode’s latest innovation for GitHub repo scanning, which enables developers to streamline activities like staging servers and environments so they don’t need to scan every time. This makes it easier for development and security teams to collaborate on secure coding and scanning as Veracode results are delivered to GitHub where developers can act immediately.
Security Debt Reduction: Veracode Fix in the IDE & Batch Fix
Research shows 92 percent of U.S.-based developers are already using artificial intelligence (AI) coding tools both in and outside of work, with generative AI helping software engineers write code 35-45 percent faster. At the same time, other research suggests code developed by AI contains the same percentage of security flaws as that generated by humans.
Veracode was the first company to deliver a solution that provides developers with AI-generated secure code fixes. Since launching Veracode Fix at RSA Conference last year, hundreds of customers have used the solution to reduce their backlog of security debt and risk. Ninety-two percent of CWEs (Common Weakness Enumeration) with a severity rating from medium to very high can be addressed through AI-generated code edits from Veracode Fix.
With the introduction of Veracode Fix in the IDE, developers can now fix flaws faster with AI-suggested remediation right in the IDE, without switching applications or researching alternative code options. Fixes can be made before code is pushed through the software development lifecycle, dramatically cutting the time and cost spent fixing flaws compared to retroactive remediation.
Batch Fix enables bulk AI-assisted remediation of flaws in source code across multiple flaws and files in one operation. This makes remediation of flaws an order of magnitude faster, aiding the reduction of security debt at scale. For example, developers can use it to fix a CWE that requires an easy-to-test resolution and run it across multiple source files at once.
Jarrett closed, “With these latest innovations, Veracode meets developers where they are—in the tools they use daily—to help them secure the code they create today, without compromising productivity. This vastly improves efficiency and velocity, fostering a culture of collaboration and trust between development and security teams.”
Repo Risk Visibility & Analysis, Veracode Fix in the IDE, and Batch Fix are available immediately. For more information, please visit the Veracode blog.
Visitors to RSA Conference can learn more about Veracode’s platform and these new features by visiting Veracode’s booth #2045 in the main hall.
About Veracode
Veracode is a global leader in Application Risk Management for the AI era. Powered by trillions of lines of code scans and a proprietary AI-assisted remediation engine, the Veracode platform is trusted by organizations worldwide to build and maintain secure software from code creation to cloud deployment. Thousands of the world’s leading development and security teams use Veracode every second of every day to get accurate, actionable visibility of exploitable risk, achieve real-time vulnerability remediation, and reduce their security debt at scale. Veracode is a multi-award-winning company offering capabilities to secure the entire software development life cycle, including Veracode Fix, Static Analysis, Dynamic Analysis, Software Composition Analysis, Container Security, Application Security Posture Management, and Penetration Testing.
Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and Twitter.
Copyright © 2024 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240501107223/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom